ArticleThe Journal of antibiotics2026
Biological profiling of structurally diverse LEGO-LPPOs reveals differences in antibacterial activity, cytocompatibility, and in vivo tolerability.
Article in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lipophosphonoxins represent a promising class of membrane-active antimicrobial agents with potential relevance for skin-targeted antimicrobial applications. Antibacterial activity of a panel of LEGO-lipophosphonoxin (LEGO-LPPO) compounds was evaluated by minimum inhibitory concentration (MIC) profiling against selected Gram-positive and Gram-negative bacterial strains. Cellular responses were subsequently assessed in human keratinocytes (HaCaT) and primary human dermal fibroblasts using MTS-based viability assays after 3 and 7 days of exposure across a broad concentration range. The tested LEGO-LPPOs exhibited pronounced variability in antibacterial activity and cytotoxicity profiles. Cell-based screening revealed marked heterogeneity in cellular responses, with fibroblasts consistently showing higher sensitivity than keratinocytes, particularly under prolonged exposure. Based on integrated MIC and IC₅₀ profiles, four representative compounds (DR_527P1, DR_556P1, DR_34P1, and DR_33P1) were selected for further functional characterization using keratinocyte migration assays, cytoskeletal organization analysis, and protein expression profiling. These compounds exerted distinct effects on cell migration, cytoskeletal organization and protein expression. In addition, in vivo tolerability was evaluated by maximal tolerated dose assessment in mice to provide a translational perspective on compound safety. Collectively, these findings show that selected structurally diverse LEGO-LPPO derivatives display divergent biological profiles that are not predicted by antibacterial potency alone. Rather than establishing a comprehensive structure-activity relationship (SAR), this study provides integrated biological profiling of representative LEGO-LPPO compounds and identifies structural diversity points and biological liabilities that should be considered during further optimization for local anti-infective applications.
Identifiers
42613366What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.